Clinical trial results of Zytiga, a new drug from Johnson & Johnson, showed incredible promise in the fight of prostate cancer. Shortly after the findings were presented at the year’s biggest cancer conference, a statistician raised concerns that the clinical trial had been stopped prematurely, which gave the impression the drug was more effective than it is. Helping to decide when clinical trials should stop or continue are data safety monitoring boards. DSMBs watch for emerging side effects, evidence that the drug does not work, or that the drug is so effective that it is no longer ethical to give patients a placebo. Statisticians are concerned over a recent trend by DSMBs to stop trials early. There’ve been times when stopped-early studies proved the benefits of several new drugs, but, in the case of Zytiga, the results were not far more statistically significant than normal.
Many clients have little or no protection for their ability to earn a paycheck.
In responses to an employee retention question, disability benefits ranked a little ahead of dental insurance.
Sales of non-variable annuities went in a different direction.
Sponsored by NGL
Help your clients plan for their future now so final expenses don’t overwhelm their loved ones later.
Don’t miss crucial news and insights you need to make informed investment advisory decisions. Join ThinkAdvisor.com now!
- Free unlimited access to ThinkAdvisor.com which provides advisors, like you, with comprehensive coverage of the products, services and trends necessary to guide your clients in making critical wealth, health and life decisions.
- Exclusive discounts on ALM and ThinkAdvisor events.
- Access to other award-winning ALM websites including TreasuryandRisk.com and Law.com.
Copyright © 2020 ALM Media Properties, LLC. All Rights Reserved.